Quantum autoencoders via quantum adders with genetic algorithms

The quantum autoencoder is a recent paradigm in the field of quantum machine learning, which may enable an enhanced use of resources in quantum technologies. To this end, quantum neural networks with less nodes in the inner than in the outer layers were considered. Here, we propose a useful connection between approximate quantum adders and quantum autoencoders. Specifically, this link allows us to employ optimized approximate quantum adders, obtained with genetic algorithms, for the implementation of quantum autoencoders for a variety of initial states. Furthermore, we can also directly optimize the quantum autoencoders via genetic algorithms. Our approach opens a different path for the design of quantum autoencoders in controllable quantum platforms

A new web-based genomics resource for bioinformatics analysis of Rhipicephalus (Boophilus) microplus: CattleTickBase

No abstract availabl

High Rate Report Synchrophasor Technique during Dynamic Conditions

139–143Current industrial applications of synchrophasors in intelligent grids depend to a great extent on highly trustable measurements, mainly during dynamic conditions of a power system, like a power swing which exhibits simultaneous variations of amplitude and phase in both voltage and current. This work presents the assessment of the performance of a novel synchrophasor technique following tests of the dynamic section of the IEEE Std. C37.118.1-2011, which requests testing the simultaneous variations of amplitude and phase

The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats

Vitamin D derivatives and calcimimetics are used to treat secondary hyperparathyroidism in patients with chronic renal failure. We investigated the effect of calcitriol, paricalcitol, and the calcimimetic AMG 641 on soft-tissue calcification in uremic rats with secondary hyperparathyroidism. Control and uremic rats were treated with vehicle, calcitriol, paricalcitol, AMG 641, or a combination of AMG 641 plus calcitriol or paricalcitol. Parathyroid hormone levels were reduced by all treatments but were better controlled by the combination of paricalcitol and AMG 641. The calcimimetic alone did not induce extraosseous calcification but co-administration of AMG 641 reduced soft-tissue calcification and aortic mineralization in both calcitriol- and paricalcitol-treated rats. Survival was significantly reduced in rats treated with calcitriol and this mortality was attenuated by co-treatment with AMG 641. Our study shows that extraskeletal calcification was present in animals treated with calcitriol and paricalcitol but not with AMG 641. When used in combination with paricalcitol, AMG 641 provided excellent control of secondary hyperparathyroidism and prevented mortality associated with the use of vitamin D derivatives without causing tissue calcification